CA3146837A1 - Compound for combination treatment - Google Patents

Compound for combination treatment Download PDF

Info

Publication number
CA3146837A1
CA3146837A1 CA3146837A CA3146837A CA3146837A1 CA 3146837 A1 CA3146837 A1 CA 3146837A1 CA 3146837 A CA3146837 A CA 3146837A CA 3146837 A CA3146837 A CA 3146837A CA 3146837 A1 CA3146837 A1 CA 3146837A1
Authority
CA
Canada
Prior art keywords
compound
age
subject
treatment
adult male
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3146837A
Other languages
English (en)
French (fr)
Inventor
Ulf Simonsen
Simon COMERMA-STEFFENSEN
Dan Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Initiator Pharma AS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3146837A1 publication Critical patent/CA3146837A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
CA3146837A 2019-08-06 2020-08-06 Compound for combination treatment Pending CA3146837A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19190224.6 2019-08-06
EP19190224 2019-08-06
PCT/EP2020/072092 WO2021023805A1 (en) 2019-08-06 2020-08-06 Compound for combination treatment

Publications (1)

Publication Number Publication Date
CA3146837A1 true CA3146837A1 (en) 2021-02-11

Family

ID=67551141

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3146837A Pending CA3146837A1 (en) 2019-08-06 2020-08-06 Compound for combination treatment

Country Status (16)

Country Link
US (1) US20220288052A1 (https=)
EP (2) EP4009942B1 (https=)
JP (1) JP7605825B2 (https=)
KR (1) KR20220054593A (https=)
CN (1) CN114430679A (https=)
AU (1) AU2020326244B2 (https=)
BR (1) BR112022002169A2 (https=)
CA (1) CA3146837A1 (https=)
DK (1) DK4009942T3 (https=)
ES (1) ES2962648T3 (https=)
FI (1) FI4009942T3 (https=)
IL (1) IL290319B2 (https=)
MX (1) MX2022000356A (https=)
PL (1) PL4009942T3 (https=)
WO (1) WO2021023805A1 (https=)
ZA (1) ZA202200723B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4646204A1 (en) * 2023-01-03 2025-11-12 Initiator Pharma A/S Compound for treatment of erectile dysfunction
WO2025051846A1 (en) 2023-09-05 2025-03-13 Initiator Pharma A/S Compound for treatment of female sexual dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04012693A (es) * 2002-06-20 2005-03-23 Lundbeck & Co As H Terapia de combinacion en donde se utiliza un inhibidor de recaptacion de serotonina.
RU2354377C2 (ru) * 2003-07-11 2009-05-10 Берингер Ингельхайм Ветмедика Гмбх Способ лечения или предупреждения заболеваний центральной нервной системы с использованием соединений, обладающих селективностью в отношении альфа-3-субъединицы бензодиазепинового рецептора
BRPI0515261A (pt) * 2004-09-30 2008-07-15 Neurosearch As composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
WO2008074798A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
BRPI0917802A2 (pt) * 2008-08-21 2016-03-01 Neurosearch As método para tratar um distúrbio de ansiedade, composição farmacêutica, uso do composto, uso de uma combinação, kit de partes, método para tratar, prevenir ou aliviar um distúrbio de ansiedade de um corpo de animal vivo, e, combinação
US20130040985A1 (en) 2010-01-29 2013-02-14 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
WO2021023805A1 (en) 2021-02-11
MX2022000356A (es) 2022-05-11
FI4009942T3 (fi) 2023-09-26
CN114430679A (zh) 2022-05-03
ES2962648T3 (es) 2024-03-20
BR112022002169A2 (pt) 2022-06-07
AU2020326244B2 (en) 2025-06-05
AU2020326244A1 (en) 2022-03-17
IL290319A (en) 2022-04-01
IL290319B2 (en) 2023-06-01
DK4009942T3 (da) 2023-10-23
EP4009942B1 (en) 2023-08-09
EP4009942A1 (en) 2022-06-15
ZA202200723B (en) 2022-08-31
EP4241839A2 (en) 2023-09-13
JP7605825B2 (ja) 2024-12-24
US20220288052A1 (en) 2022-09-15
JP2022544463A (ja) 2022-10-19
PL4009942T3 (pl) 2024-04-08
EP4241839A3 (en) 2023-11-15
KR20220054593A (ko) 2022-05-03

Similar Documents

Publication Publication Date Title
RU2458691C2 (ru) Лечение посттравматического стрессового расстройства
CN101815438A (zh) 治疗依赖性的方法
EP3013342B1 (en) Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
CN117202907A (zh) 用于延迟人类男性的射精的方法
US20040019101A1 (en) Methods of treating gastrointestinary and genitourinary pain disorders
AU2020326244B2 (en) Compound for combination treatment
AU2014248928B2 (en) Onapristone polymorphic forms and methods of use
CN101346143A (zh) 治疗女性性功能障碍的包含他达拉非的药物剂型
HK40099487A (en) Compound for combination treatment
HK40071713B (en) Compound for combination treatment
HK40071713A (en) Compound for combination treatment
BR112020017026A2 (pt) 3ss-(4-metoxibenziloxi)pregn-5-en-20-ona para uso no tratamento de transtornos relacionados a canabinoides
US20230372364A1 (en) Method of treating gaba mediated disorders
Mody et al. In search of novel and therapeutically significant melatoninergic ligands
CN115006346B (zh) 精神疾病治疗剂的稳定化方法和包含阿米替林的组合物
EP2329824A1 (en) Novel pharmaceutical composition for treatment of nociceptive pain
CN104254539A (zh) 抗糖尿病的氨基甾族化合物衍生物
WO2014177065A1 (zh) 一种六氢二苯并[a,g]喹嗪类化合物的药物用途
STEINHEYER et al. Basic and Clinical Aspects of Depression
HK1155063A (en) Treatment of post-traumatic stress disorder
Haddley Lu-AA-21004
US20080176951A1 (en) Methods of treating gastrointestinary and genitourinary pain disorders
JP2010222347A (ja) Ｐｄｅ５阻害剤及びカルニチンを含有する医薬組成物
JP2009057303A (ja) 中枢性排尿障害の治療剤
NZ624056A (en) Compositions of buprenorphine and mu-opioid receptor antagonists

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240729

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240729

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240802

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240802

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240802

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241118

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241118

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241118

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250410

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250716

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250716

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250718

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251114

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260113

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260113